Literature DB >> 1528955

Multistage carcinogenesis in mouse skin.

J DiGiovanni1.   

Abstract

The mouse skin model of multistage carcinogenesis has for many years provided a conceptual framework for studying carcinogenesis mechanisms and potential means for inhibiting specific stages of carcinogenesis. The process of skin carcinogenesis involves the stepwise accumulation of genetic change ultimately leading to malignancy. Initiation, the first step in multistage skin carcinogenesis involves carcinogen-induced genetic changes. A target gene identified for some skin tumor initiators is c-Ha-ras. The second step, the promotion stage, involves processes whereby initiated cells undergo selective clonal expansion to form visible premalignant lesions termed papillomas. The process of tumor promotion involves the production and maintenance of a specific and chronic hyperplasia characterized by a sustained cellular proliferation of epidermal cells. These changes are believed to result from epigenetic mechanisms such as activation of the cellular receptor, protein kinase C, by some classes of tumor promoters. The progression stage involves the conversion of papillomas to malignant tumors, squamous cell carcinomas. The accumulation of additional genetic changes in cells comprising papillomas has been correlated with tumor progression, including trisomies of chromosomes 6 and 7 and loss of heterozygosity. The current review focuses on the mechanisms involved in multistage skin carcinogenesis, a summary of known inhibitors of specific stages and their proposed mechanisms of action, and the relevance of this model system to human cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528955     DOI: 10.1016/0163-7258(92)90051-z

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  125 in total

Review 1.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

2.  Conjugated linoleic acid modulation of phorbol ester-induced events in murine keratinocytes.

Authors:  K L Liu; M A Belury
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

3.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

4.  Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.

Authors:  Panomwat Amornphimoltham; Kantima Leelahavanichkul; Alfredo Molinolo; Vyomesh Patel; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

5.  Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors.

Authors:  P Auewarakul; L Gissmann; A Cid-Arregui
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

6.  Regio- and stereoselective metabolism of 7,12-dimethylbenz[a]anthracene by Mycobacterium vanbaalenii PYR-1.

Authors:  Joanna D Moody; Peter P Fu; James P Freeman; Carl E Cerniglia
Journal:  Appl Environ Microbiol       Date:  2003-07       Impact factor: 4.792

7.  Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis.

Authors:  Nabiha Yusuf; Tahseen H Nasti; Sreelatha Meleth; Craig A Elmets
Journal:  Mol Carcinog       Date:  2009-08       Impact factor: 4.784

Review 8.  A review of coumarin derivatives in pharmacotherapy of breast cancer.

Authors:  Musiliyu A Musa; John S Cooperwood; M Omar F Khan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Chemopreventive potential of Epoxy clerodane diterpene from Tinospora cordifolia against diethylnitrosamine-induced hepatocellular carcinoma.

Authors:  Muniyappan Dhanasekaran; Arul-Albert Baskar; Savarimuthu Ignacimuthu; Paul Agastian; Veeramuthu Duraipandiyan
Journal:  Invest New Drugs       Date:  2008-10-14       Impact factor: 3.850

10.  Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Authors:  Brett Schrand; Alexey Berezhnoy; Randall Brenneman; Anthony Williams; Agata Levay; Ling-Yuan Kong; Ganesh Rao; Shouhao Zhou; Amy B Heimberger; Eli Gilboa
Journal:  Cancer Immunol Res       Date:  2014-06-17       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.